Last reviewed · How we verify
MK0941
At a glance
| Generic name | MK0941 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005) (PHASE1)
- Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027) (PHASE1)
- A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017) (PHASE2)
- A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018) (PHASE2)
- An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006) (PHASE1)
- A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED) (PHASE1)
- Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009) (PHASE1)
- MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011). (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0941 CI brief — competitive landscape report
- MK0941 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI